European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

10th CEM: key messages on hormonal therapy of prostate cancer

Issues regarding the hormonal therapy of prostate cancer were discussed in the second plenary session at the 10th Central European Meeting (CEM).

Mon, 25 Oct 2010
Prostate CancerOncologyCentral European MeetingAndrogen Therapy

October 2010 - Issues regarding the hormonal therapy of prostate cancer were discussed in the second plenary session at the 10th Central European Meeting (CEM) held yesterday in Bratislava, Slovakia. Chaired by M, Sosnowski and V. Student, the session featured Per-Anders Abrahamsson, George Thalman and R. Zachoval as speakers.

Prof. Per-Anders Abrahamsson spoke on the pros and cons of androgen deprivation., addressing the issue of what is new in androgen therapy (ADT) Abrahamsson discussed new agents, new concerns about efficacy of intracellular testosterone suppression, better selection of indications and better understanding of side effects.

"It’s time to promote a holistic view of ADT," said Abrahamsson as he examined concerns such as hidden toxicities and the need for a more 'global' patient approach. He said that for patients who really needed ADT, they should take precautionary measures such as regular physical exercise, stop smoking, improving their diet, undergoing a cardiovascular evaluation, monitoring glycerin and serum lipids, and the use of cholesterol-lowering agents, amongst others.

In his take-home messages regarding intermittent androgen therapy (IAD), Abrahamsson highlighted the following:

  • Evidence from clinical trials is poor (only one mature phase 3 trial so far
  • More questions than answers, such as patient selection, when to stop or resume the therapy, what kind of therapy, etc..
  • IAD remains an experimental approach (according to EAU Guidelines)

Meanhile, Thalmann addressed the issue of managing bone metastasis in urological diseases, looking at skeletal complications , the prognostic factors in cancer with bone metastases and the traditional treatment approaches to urological bone metastases such as radiotherapy, hormonal therapy in prostate cancer, analgesic, orthopedic interventions, chemotherapy, radionucleotides and drugs.

In his concluding remarks, Thalmann said bone metastases are a source of considerable morbidity and that given the possibilities that physicians have, no patient should suffer, He also mentioned the issue of employing focal therapy vis-à-vis systemic therapy.

Roman Zachoval, on the other hand, tackled the challenges regarding hormonal therapy in castrate resistant prostate cancer (CRPC) and discussed various potential therapeutic options in CRPC.

Share this article

Suggested for you

See all
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer